Mira Pharmaceuticals Relocates HQ
Ticker: MIRA · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
Mira Pharma moved its HQ to Miami. Big changes coming?
AI Summary
Mira Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting "Other Events." The filing indicates a change in the company's principal executive offices to 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131. The company was formerly known as Mira1a Therapeutics, Inc., with a name change effective January 12, 2022.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments for the company.
Risk Assessment
Risk Level: low — The filing reports a change in address, which is a routine administrative event with no immediate financial or operational risk.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- March 4, 2025 (date) — Filing Date
- 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131 (location) — New Principal Executive Offices
- Mira1a Therapeutics, Inc. (company) — Former Company Name
- January 12, 2022 (date) — Date of Name Change
FAQ
What is the new address for Mira Pharmaceuticals, Inc.'s principal executive offices?
The new address is 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
When was this 8-K filing submitted?
The filing was submitted on March 4, 2025.
What was Mira Pharmaceuticals, Inc. previously named?
The company was formerly known as Mira1a Therapeutics, Inc.
When did the company change its name from Mira1a Therapeutics, Inc.?
The date of the name change was January 12, 2022.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding MIRA PHARMACEUTICALS, INC. (MIRA).